132 related articles for article (PubMed ID: 23318602)
1. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.
Ouzan D; Pénaranda G; Joly H; Halfon P
J Hepatol; 2013 Jun; 58(6):1258-9. PubMed ID: 23318602
[No Abstract] [Full Text] [Related]
2. Current management of delta hepatitis.
Rizzetto M
Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
[TBL] [Abstract][Full Text] [Related]
3. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
[TBL] [Abstract][Full Text] [Related]
5. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
[TBL] [Abstract][Full Text] [Related]
6. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa.
Maraolo AE; Minervini F; Tosone G
Aliment Pharmacol Ther; 2015 Mar; 41(6):595. PubMed ID: 25659214
[No Abstract] [Full Text] [Related]
7. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa--authors' reply.
Koh C; Heller T
Aliment Pharmacol Ther; 2015 Mar; 41(6):595-6. PubMed ID: 25659215
[No Abstract] [Full Text] [Related]
8. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
[TBL] [Abstract][Full Text] [Related]
9. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
Guedj J; Rotman Y; Cotler SJ; Koh C; Schmid P; Albrecht J; Haynes-Williams V; Liang TJ; Hoofnagle JH; Heller T; Dahari H
Hepatology; 2014 Dec; 60(6):1902-10. PubMed ID: 25098971
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon therapy of chronic hepatitis D: in need of revision.
Rizzetto M; Smedile A
Hepatology; 2015 Apr; 61(4):1109-11. PubMed ID: 25348580
[No Abstract] [Full Text] [Related]
11. Can We Predict Sustained Virologic Response to Interferon α Therapy in Patients With Chronic Hepatitis Delta Virus Infection?
Scholtès C; Kumar R; Zoulim F
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2350-2. PubMed ID: 26254201
[No Abstract] [Full Text] [Related]
12. Resolution of chronic hepatitis delta infection after five years of peginterferon-adefovir: lessons from a case report.
Brichler S; Setshedi M; Renou C
Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):e81-4. PubMed ID: 23433964
[TBL] [Abstract][Full Text] [Related]
13. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
[TBL] [Abstract][Full Text] [Related]
14. [Quantification of hepatitis B virus HBsAg: clinical implications].
Buti M; Rodríguez Frías F; Esteban R
Med Clin (Barc); 2012 Apr; 138(11):483-8. PubMed ID: 21719049
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
[TBL] [Abstract][Full Text] [Related]
16. Treatment of delta hepatitis.
Gunsar F
Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis delta chronic infection: HBs antigen quantification may help monitoring, and HBs antigen seroconversion could be the ideal 'end' point of treatment.
Brichler S; Setshedi M; Renou C
J Clin Virol; 2012 Sep; 55(1):83-4. PubMed ID: 22727681
[No Abstract] [Full Text] [Related]
18. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
Yang F; Wu XF; Li XH; Wei N
Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
[No Abstract] [Full Text] [Related]
19. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
[TBL] [Abstract][Full Text] [Related]
20. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]